In a news release, Nate Hill, the compounders CEO, characterized the lawsuit as a fight for the right of every patient to have access to the medicine their doctor prescribes, at a price that isnt dictated by a monopoly. The pharmaceutical companies have already responded to the competition by offering dramatically lower cash prices for their drugs, with Eli Lilly offering a starting dose of tirzepatide for $300 and Novo selling a starting dose of semaglutide for $350
The drug was manufactured by Renata PLC in Bangladesh
whether GLP-1RA or dual agonists can maintain renoprotection and attenuate late-stage heart-failure progression beyond a decade remains unknown
After reconstitution, keep solutions refrigerated at 4C and use within manufacturer-recommended timeframes to maintain full compound integrity
Track your body through the journey, free
"We know there are people who are interested in addressing their weight but have been waiting on the sidelines for a medicine that was right for them," Ed Cinca, senior vice president of marketing & patient solutions at Novo Nordisk said in the press release
